BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aoki Y, Narazaki M, Kishimoto T, Tosato G. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. Blood 2001;98:3042-9. [PMID: 11698289 DOI: 10.1182/blood.v98.10.3042] [Cited by in Crossref: 55] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Cousins E, Nicholas J. Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication. Recent Results Cancer Res. 2014;193:227-268. [PMID: 24008302 DOI: 10.1007/978-3-642-38965-8_13] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
2 Dela Cruz CS, Viswanathan SR, El-Guindy AS, Shedd D, Miller G. Complex N-linked glycans on Asn-89 of Kaposi sarcoma herpes virus-encoded interleukin-6 mediate optimal function by affecting cytokine protein conformation. J Biol Chem 2009;284:29269-82. [PMID: 19690161 DOI: 10.1074/jbc.M109.039115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
3 Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012;8:1227-36. [PMID: 23136551 DOI: 10.7150/ijbs.4666] [Cited by in Crossref: 144] [Cited by in F6Publishing: 140] [Article Influence: 14.4] [Reference Citation Analysis]
4 Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295. [PMID: 25190079 DOI: 10.1101/cshperspect.a016295] [Cited by in Crossref: 1219] [Cited by in F6Publishing: 1155] [Article Influence: 152.4] [Reference Citation Analysis]
5 Gasperini P, Sakakibara S, Tosato G. Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis. J Leukoc Biol 2008;84:994-1000. [PMID: 18319288 DOI: 10.1189/jlb.1107777] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sakakibara S, Tosato G. Contribution of viral mimics of cellular genes to KSHV infection and disease. Viruses 2014;6:3472-86. [PMID: 25243371 DOI: 10.3390/v6093472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Giffin L, West JA, Damania B. Kaposi's Sarcoma-Associated Herpesvirus Interleukin-6 Modulates Endothelial Cell Movement by Upregulating Cellular Genes Involved in Migration. mBio 2015;6:e01499-15. [PMID: 26646010 DOI: 10.1128/mBio.01499-15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
8 Ramaswami R, Lurain K, Yarchoan R. Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. J Clin Oncol 2021;:JCO2102040. [PMID: 34890242 DOI: 10.1200/JCO.21.02040] [Reference Citation Analysis]
9 Labò N, Ohnuki H, Tosato G. Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. Cells 2020;9:E1583. [PMID: 32629875 DOI: 10.3390/cells9071583] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
10 Underhill-Day N, McGovern LA, Karpovich N, Mardon HJ, Barton VA, Heath JK. Functional characterization of W147A: a high-affinity interleukin-11 antagonist. Endocrinology 2003;144:3406-14. [PMID: 12865319 DOI: 10.1210/en.2002-0144] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
11 Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med 2020;217:e20190347. [PMID: 32267936 DOI: 10.1084/jem.20190347] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
12 Hopcraft SE, Pattenden SG, James LI, Frye S, Dittmer DP, Damania B. Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog 2018;14:e1007267. [PMID: 30212584 DOI: 10.1371/journal.ppat.1007267] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
13 Direkze S, Laman H. Regulation of growth signalling and cell cycle by Kaposi's sarcoma-associated herpesvirus genes. Int J Exp Pathol 2004;85:305-19. [PMID: 15566428 DOI: 10.1111/j.0959-9673.2004.00407.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
14 Rivera-Soto R, Dissinger NJ, Damania B. Kaposi's Sarcoma-Associated Herpesvirus Viral Interleukin-6 Signaling Upregulates Integrin β3 Levels and Is Dependent on STAT3. J Virol 2020;94:e01384-19. [PMID: 31801855 DOI: 10.1128/JVI.01384-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
15 Giffin L, Yan F, Ben Major M, Damania B. Modulation of Kaposi's sarcoma-associated herpesvirus interleukin-6 function by hypoxia-upregulated protein 1. J Virol 2014;88:9429-41. [PMID: 24920810 DOI: 10.1128/JVI.00511-14] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
16 Kovaleva M, Bussmeyer I, Rabe B, Grötzinger J, Sudarman E, Eichler J, Conrad U, Rose-John S, Scheller J. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol 2006;80:8510-20. [PMID: 16912301 DOI: 10.1128/JVI.00420-06] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
17 Chen D, Nicholas J. Structural requirements for gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence for gp80 stabilization of gp130 signaling complexes induced by vIL-6. J Virol 2006;80:9811-21. [PMID: 16973585 DOI: 10.1128/JVI.00872-06] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
18 Dela Cruz CS, Lee Y, Viswanathan SR, El-Guindy AS, Gerlach J, Nikiforow S, Shedd D, Gradoville L, Miller G. N-linked glycosylation is required for optimal function of Kaposi's sarcoma herpesvirus-encoded, but not cellular, interleukin 6. J Exp Med 2004;199:503-14. [PMID: 14970177 DOI: 10.1084/jem.20031205] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
19 Hu D, Wang V, Yang M, Abdullah S, Davis DA, Uldrick TS, Polizzotto MN, Veeranna RP, Pittaluga S, Tosato G, Yarchoan R. Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1. J Virol 2016;90:368-78. [PMID: 26491160 DOI: 10.1128/JVI.01192-15] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
20 Espígol-Frigolé G, Planas-Rigol E, Ohnuki H, Salvucci O, Kwak H, Ravichandran S, Luke B, Cid MC, Tosato G. Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling. Sci Signal 2016;9:ra28. [PMID: 26980441 DOI: 10.1126/scisignal.aad2357] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
21 Goto H, Kudo E, Kariya R, Taura M, Katano H, Okada S. Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. J Cancer Res Clin Oncol 2015;141:465-74. [PMID: 25304617 DOI: 10.1007/s00432-014-1842-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
22 Sakakibara S, Tosato G. Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res 2011;31:791-801. [PMID: 21767154 DOI: 10.1089/jir.2011.0043] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
23 Kang JG, Majerciak V, Uldrick TS, Wang X, Kruhlak M, Yarchoan R, Zheng ZM. Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. J Pathol 2011;225:378-89. [PMID: 21984125 DOI: 10.1002/path.2962] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
24 Gasperini P, Tosato G. Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma. Leukemia 2009;23:1867-74. [PMID: 19554030 DOI: 10.1038/leu.2009.117] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
25 Giffin L, Damania B. KSHV: pathways to tumorigenesis and persistent infection. Adv Virus Res. 2014;88:111-159. [PMID: 24373311 DOI: 10.1016/b978-0-12-800098-4.00002-7] [Cited by in Crossref: 84] [Cited by in F6Publishing: 58] [Article Influence: 10.5] [Reference Citation Analysis]
26 Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr Opin Oncol 2012;24:495-505. [PMID: 22729151 DOI: 10.1097/CCO.0b013e328355e0f3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 25] [Article Influence: 5.9] [Reference Citation Analysis]
27 Ramaswami R, Lurain K, Peer CJ, Serquiña A, Wang V, Widell A, Goncalves P, Steinberg SM, Marshall V, George J, Figg WD, Whitby D, Ziegelbauer J, Uldrick TS, Yarchoan R. Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 2020;135:2316-9. [PMID: 32276276 DOI: 10.1182/blood.2019004602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]